Edition:
United States

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

13.85USD
4:00pm EDT
Change (% chg)

$0.15 (+1.09%)
Prev Close
$13.70
Open
$13.75
Day's High
$14.00
Day's Low
$13.70
Volume
73,435
Avg. Vol
110,755
52-wk High
$20.68
52-wk Low
$10.77

VIVO.OQ

Chart for VIVO.OQ

About

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $578.18
Shares Outstanding(Mil.): 42.20
Dividend: 0.12
Yield (%): 3.65

Financials

  VIVO.OQ Industry Sector
P/E (TTM): 19.52 30.96 17.29
EPS (TTM): 0.70 -- --
ROI: 12.72 12.88 -5.84
ROE: 17.52 15.34 -5.23

BRIEF-Meridian Bioscience comments on FDA matter involving its subsidiary

* Meridian Bioscience comments on FDA matter involving its subsidiary, Magellan Diagnostics

May 17 2017

BRIEF-Meridian Bioscience says CEO John Kraeutler to retire

* Meridian Bioscience engages Korn Ferry to conduct CEO search as John Kraeutler announces plans to retire

May 10 2017

BRIEF-Meridian Bioscience sees FY 2017 revenue $193 mln to $199 mln

* Meridian bioscience reports second quarter 2017 operating results, declares regular cash dividend, and reaffirms fiscal 2017 guidance

Apr 27 2017

BRIEF-Meridian Bioscience Inc signs an exclusive distribution agreement with Biofirm Technologies

* Meridian Bioscience Inc- Magellan Diagnostics , a business unit signed an exclusive distribution agreement with Biofirm Technologies Source text for Eikon: Further company coverage:

Mar 07 2017

BRIEF-Meridian Bioscience Q1 earnings per share $0.15

* Meridian Bioscience reports first quarter 2017 operating results, reduces regular cash dividend, and revises fiscal 2017 guidance downward

Jan 25 2017

More From Around the Web

Competitors

Earnings vs. Estimates